Business Segments and Geographic Information

The Company has five reportable segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical and Skeletal Health. Certain reportable segments represent an aggregation of operating units within each segment. The Company measures and evaluates its reportable segments based on segment revenues and operating income adjusted to exclude the effect of non-cash charges, such as intangible asset amortization expense, intangible asset and goodwill impairment charges, acquisition related fair value adjustments and integration expenses, restructuring, divestiture and facility consolidation charges and other one-time or unusual items.

Identifiable assets for the five principal operating segments consist of inventories, intangible assets, goodwill, and property, plant and equipment. The Company fully allocates depreciation expense to its five reportable segments. The Company has presented all other identifiable assets as corporate assets. There were no inter-segment revenues during the three and six months ended March 30, 2019 and March 31, 2018. Segment information is as follows:



	Three Months Ended						Six Months Ended
	March 30, 2019			March 31, 2018			March 30, 2019			March 31, 2018
Total revenues:
Diagnostics	$	296.7		$	279.7		$	593.3		$	564.3
Breast Health	321.5			300.1			646.2			588.1
Medical Aesthetics	73.8			85.5			153.6			176.8
GYN Surgical	102.2			99.4			210.6			206.9
Skeletal Health	24.2			24.6			45.4			44.3
	$	818.4		$	789.3		$	1,649.1		$	1,580.4
Income (loss) from operations:
Diagnostics	$	31.1		$	34.2		$	74.4		$	70.7
Breast Health	99.0			101.5			196.8			191.2
Medical Aesthetics	(473.9		)	(760.1		)	(499.1		)	(783.1		)
GYN Surgical	20.5			17.9			47.6			48.2
Skeletal Health	0.1			2.3			(2.4		)	2.9
	$	(323.2	)	$	(604.2	)	$	(182.7	)	$	(470.1	)
Depreciation and amortization:
Diagnostics	$	61.6		$	64.1		$	123.4		$	128.8
Breast Health	8.9			5.5			18.2			10.4
Medical Aesthetics	25.1			27.0			50.6			55.5
GYN Surgical	21.9			22.8			43.9			45.7
Skeletal Health	0.1			0.1			0.3			0.3
	$	117.6		$	119.5		$	236.4		$	240.7
Capital expenditures:
Diagnostics	$	16.0		$	14.0		$	30.4		$	25.9
Breast Health	4.7			3.8			6.8			7.3
Medical Aesthetics	3.4			3.5			4.5			5.1
GYN Surgical	3.1			3.3			6.6			5.7
Skeletal Health	0.3			0.1			0.6			0.8
Corporate	1.8			2.3			3.0			4.0
	$	29.3		$	27.0		$	51.9		$	48.8



	March 30, 2019		September 29, 2018
Identifiable assets:
Diagnostics	$	2,364.4	$	2,442.9
Breast Health	1,131.3		972.4
Medical Aesthetics	432.0		913.3
GYN Surgical	1,373.7		1,414.9
Skeletal Health	32.7		30.3
Corporate	1,191.2		1,457.1
	$	6,525.3	$	7,230.9

The reduction in identifiable assets for the Medical Aesthetics reportable segment was due to the Company recording an impairment charge of $443.8 million in the second quarter of fiscal 2019 (see Note 14).

The Company had no customers that represented greater than 10% of consolidated revenues during the three and six months ended March 30, 2019 and March 31, 2018.

The Company operates in the major geographic areas noted in the below chart. Revenue data is based upon customer location. Other than the United States, no single country accounted for more than 10% of consolidated revenues. The Company’s sales in Europe are predominantly derived from France, Germany and the United Kingdom. The Company’s sales in Asia-Pacific are predominantly derived from China, Australia and Japan. The “Rest of World” designation includes Canada, Latin America and the Middle East.

Revenues by geography as a percentage of total revenues were as follows:



	Three Months Ended				Six Months Ended
	March 30, 2019		March 31, 2018		March 30, 2019		March 31, 2018
United States	75.1	%	74.5	%	75.0	%	75.0	%
Europe	12.5	%	12.6	%	12.3	%	12.0	%
Asia-Pacific	7.9	%	7.9	%	8.1	%	8.3	%
Rest of World	4.5	%	5.0	%	4.6	%	4.7	%
	100.0	%	100.0	%	100.0	%	100.0	%